Literature DB >> 19741600

Repeated vaginal administration of trimeric HIV-1 clade C gp140 induces serum and mucosal antibody responses.

M P Cranage1, C A Fraser, Z Stevens, J Huting, M Chang, S A Jeffs, M S Seaman, A Cope, T Cole, R J Shattock.   

Abstract

Vaccine-mediated prevention of primary infection with human immunodeficiency virus (HIV) may require the sustained production of antibody at mucosal portals of entry. Here, we describe a novel approach of repeated mucosal immunization by delivering an HIV-1 envelope glycoprotein (gp) in a gel formulated for intravaginal delivery. Rabbits were immunized over one to three 19-day cycles of intravaginal dosing with soluble recombinant trimeric HIV-1 clade C gp140 administered in Carbopol gel. The formulation was well tolerated. A single immunization cycle induced immunoglobulin G (IgG) antibody detected in the serum and female genital tract, and titers were boosted on further immunization. Vaccine-induced serum antibodies neutralized the infectivity of a pseudovirus carrying a heterologous clade C envelope. Our data prove the concept that repeated exposure of the female genital tract to HIV envelope can induce mucosally detectable antibody.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19741600      PMCID: PMC3761690          DOI: 10.1038/mi.2009.110

Source DB:  PubMed          Journal:  Mucosal Immunol        ISSN: 1933-0219            Impact factor:   7.313


  33 in total

1.  Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate.

Authors:  C Devito; J Hinkula; R Kaul; L Lopalco; J J Bwayo; F Plummer; M Clerici; K Broliden
Journal:  AIDS       Date:  2000-09-08       Impact factor: 4.177

2.  Induction of an HPV 6bL1-specific mucosal IgA response by DNA immunization.

Authors:  C Schreckenberger; P Sethupathi; A Kanjanahaluethai; M Müller; J Zhou; L Gissmann; L Qiao
Journal:  Vaccine       Date:  2000-09-15       Impact factor: 3.641

3.  Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies.

Authors:  J R Mascola; G Stiegler; T C VanCott; H Katinger; C B Carpenter; C E Hanson; H Beary; D Hayes; S S Frankel; D L Birx; M G Lewis
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

Review 4.  Inhibiting sexual transmission of HIV-1 infection.

Authors:  Robin J Shattock; John P Moore
Journal:  Nat Rev Microbiol       Date:  2003-10       Impact factor: 60.633

5.  Fine mapping of an immunodominant domain in the transmembrane glycoprotein of human immunodeficiency virus.

Authors:  J W Gnann; J A Nelson; M B Oldstone
Journal:  J Virol       Date:  1987-08       Impact factor: 5.103

6.  Cervicovaginal anti-HIV antibodies in HIV-seronegative female sex workers in Abidjan, Côte d'Ivoire.

Authors:  P D Ghys; L Bélec; M O Diallo; V Ettiègne-Traoré; P Becquart; C Maurice; J N Nkengasong; I M Coulibaly; A E Greenberg; M Laga; S Z Wiktor
Journal:  AIDS       Date:  2000-11-10       Impact factor: 4.177

7.  Local antibody response to poliovaccine in the human female genital tract.

Authors:  P L Ogra; S S Ogra
Journal:  J Immunol       Date:  1973-05       Impact factor: 5.422

8.  Comparison of vaginal tolerance tests of spermicidal preparations in rabbits and monkeys.

Authors:  P Eckstein; M C Jackson; N Millman; A J Sobrero
Journal:  J Reprod Fertil       Date:  1969-10

9.  Characterization of a virtually full-length human immunodeficiency virus type 1 genome of a prevalent intersubtype (C/B') recombinant strain in China.

Authors:  L Su; M Graf; Y Zhang; H von Briesen; H Xing; J Köstler; H Melzl; H Wolf; Y Shao; R Wagner
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

10.  Vaginal delivery of the recombinant HIV-1 clade-C trimeric gp140 envelope protein CN54gp140 within novel rheologically structured vehicles elicits specific immune responses.

Authors:  Rhonda M Curran; Louise Donnelly; Ryan J Morrow; Carol Fraser; Gavin Andrews; Martin Cranage; R Karl Malcolm; Robin J Shattock; A David Woolfson
Journal:  Vaccine       Date:  2009-09-10       Impact factor: 3.641

View more
  20 in total

1.  Use of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoprotein.

Authors:  Antu K Dey; Brian Burke; Yide Sun; Karin Hartog; Jonathan L Heeney; David Montefiori; Indresh K Srivastava; Susan W Barnett
Journal:  Vaccine       Date:  2012-02-22       Impact factor: 3.641

2.  Optimized Mucosal Modified Vaccinia Virus Ankara Prime/Soluble gp120 Boost HIV Vaccination Regimen Induces Antibody Responses Similar to Those of an Intramuscular Regimen.

Authors:  Dorothy I Jones; Justin J Pollara; Brandi T Johnson-Weaver; Celia C LaBranche; David C Montefiori; David J Pickup; Sallie R Permar; Soman N Abraham; Massimo Maddaloni; David W Pascual; Herman F Staats
Journal:  J Virol       Date:  2019-06-28       Impact factor: 5.103

Review 3.  Vaginal delivery of vaccines.

Authors:  Hannah M VanBenschoten; Kim A Woodrow
Journal:  Adv Drug Deliv Rev       Date:  2021-09-01       Impact factor: 15.470

4.  Evaluation of TLR agonists as potential mucosal adjuvants for HIV gp140 and tetanus toxoid in mice.

Authors:  Viviana Buffa; Katja Klein; Lucia Fischetti; Robin J Shattock
Journal:  PLoS One       Date:  2012-12-13       Impact factor: 3.240

5.  Rational design of HIV vaccine and microbicides: report of the EUROPRISE annual conference.

Authors:  Britta Wahren; Priscilla Biswas; Marie Borggren; Adam Coleman; Kelly Da Costa; Winni De Haes; Tessa Dieltjens; Stefania Dispinseri; Katrijn Grupping; David Hallengärd; Julia Hornig; Katja Klein; Lara Mainetti; Paolo Palma; Marc Reudelsterz; Janna Seifried; Philippe Selhorst; Annette Sköld; Hannes Uchtenhagen; Marit J van Gils; Caroline Weber; Robin Shattock; Gabriella Scarlatti
Journal:  J Transl Med       Date:  2010-07-26       Impact factor: 5.531

6.  A novel strategy for inducing enhanced mucosal HIV-1 antibody responses in an anti-inflammatory environment.

Authors:  Frank Wegmann; George Krashias; Kerstin Lühn; Karoliina Laamanen; Sueli Vieira; Simon A Jeffs; Robin J Shattock; Quentin J Sattentau
Journal:  PLoS One       Date:  2011-01-06       Impact factor: 3.240

7.  Phase I randomised clinical trial of an HIV-1(CN54), clade C, trimeric envelope vaccine candidate delivered vaginally.

Authors:  David J Lewis; Carol A Fraser; Abdel N Mahmoud; Rebecca C Wiggins; Maria Woodrow; Alethea Cope; Chun Cai; Rafaela Giemza; Simon A Jeffs; Maria Manoussaka; Tom Cole; Martin P Cranage; Robin J Shattock; Charles J Lacey
Journal:  PLoS One       Date:  2011-09-30       Impact factor: 3.240

8.  Intravaginal immunization using the recombinant HIV-1 clade-C trimeric envelope glycoprotein CN54gp140 formulated within lyophilized solid dosage forms.

Authors:  Louise Donnelly; Rhonda M Curran; John S Tregoning; Paul F McKay; Tom Cole; Ryan J Morrow; Vicky L Kett; Gavin P Andrews; A David Woolfson; R Karl Malcolm; Robin J Shattock
Journal:  Vaccine       Date:  2011-04-21       Impact factor: 3.641

9.  Antibody responses after intravaginal immunisation with trimeric HIV-1 CN54 clade C gp140 in Carbopol gel are augmented by systemic priming or boosting with an adjuvanted formulation.

Authors:  Martin P Cranage; Carol A Fraser; Alethea Cope; Paul F McKay; Michael S Seaman; Tom Cole; A Nasir Mahmoud; Joanna Hall; Elaine Giles; Gerald Voss; Mark Page; Neil Almond; Robin J Shattock
Journal:  Vaccine       Date:  2010-12-25       Impact factor: 3.641

10.  Vaginal delivery of the recombinant HIV-1 clade-C trimeric gp140 envelope protein CN54gp140 within novel rheologically structured vehicles elicits specific immune responses.

Authors:  Rhonda M Curran; Louise Donnelly; Ryan J Morrow; Carol Fraser; Gavin Andrews; Martin Cranage; R Karl Malcolm; Robin J Shattock; A David Woolfson
Journal:  Vaccine       Date:  2009-09-10       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.